Veracyte, Inc. (VCYT) Valuation — DCF & Advanced Analysis | MarketCI

Navigation

Explore Analysis Investor Relations AI Assistant Compare Screener

Help Pricing Privacy Terms

Navigation

Explore Analysis Investor Relations AI Assistant Compare Screener

Help Pricing Privacy Terms

Veracyte, Inc. (VCYT) Valuation — DCF & Advanced Analysis | MarketCI | MarketCI

VCYT

Market Closed

Veracyte, Inc.

NASDAQHealthcare Medical - Diagnostics & Research

755 employees

CEO: Marc Stapley

Founded: 2013

$59.12

+$0.00(+NaN%)

Market Cap

4.72B

Beta

1.93

52W Range

N/A

Dividend Yield

0.00%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

Comprehensive Valuation

In-depth valuation analysis including DCF scenarios and peer comparisons.

AI Insight: Veracyte's current price exceeds all weighted valuation methods, indicating potential overvaluation with a -34.0% implied downside. Strong liquidity contrasts weak profitability and efficiency scores, highlighting financial stability amid operational challenges. Monte Carlo analysis shows 100% downside risk scenarios, signaling high valuation volatility and risk.

Enhanced Football Field Analysis

Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore VCYT

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples